You are here: Industry Insights > AffaMed

News List

AffaMed Therapeutics Announces Approval for the Phase IIb Clinical Study of AM006 in China for the Treatment of Parkinson's Disease prnasia
May 28, 2021
AffaMed Therapeutics, a global clinical stage biopharmaceutical company dedicated to addressing critical unmet medical needs in ophthalmic, neurological and psychiatric disorders, today announced that China's National Medical Products Administration ...
AffaMed Therapeutics Announces Appointment of Vijay Karwal as Chief Financial Officer prnasia
May 17, 2021
AffaMed Therapeutics, a global clinical stage biopharmaceutical company dedicated to addressing critical unmet medical needs in ophthalmic, neurological and psychiatric disorders, today announced the appointment of Vijay Karwal as Chief Financial Officer.
AffaMed Therapeutics and SIFI Announce Joint Venture to Serve Greater China Market prnasia
March 31, 2021
AffaMed Therapeutics, a global clinical-stage biopharmaceutical company dedicated to addressing critical unmet patient need in ophthalmic, neurological and psychiatric disorders, and SIFI S.p.A., a leading international ophthalmic company, today ...
AffaMed Therapeutics Announces Completion of over US$170 Million Series B Financing Led by Lake Bleu Capital to Further Development of Ophthalmic and Neuroscience Pipeline prnasia
March 30, 2021
AffaMed Therapeutics, a global clinical-stage biopharmaceutical company dedicated to addressing critical unmet patient need in ophthalmic, neurological and psychiatric disorders, today announced the completion of over US$170 million in Series B financing.